胃饥饿素系统参与羟考酮自我给药的维持:来自内分泌、药理学和转基因方法的汇聚证据
研究在大鼠中探究内源性胃饥饿素系统与羟考酮自我给药的相互作用,并在小鼠中检验胃饥饿素系统对中脑奖赏环路光遗传脑刺激奖赏的作用。羟考酮自我给药升高血浆胃饥饿素、去酰基胃饥饿素和生长激素,上调VTA多巴胺神经元GHS-R1a mRNA;GHS-R1a拮抗剂JMV2959剂量依赖性减少羟考酮自我给药并降低渐进比率下的突破点,该效应在GHS-R敲除大鼠中消失。作者认为胃饥饿素信号升高是羟考酮动机性摄药的原因性过程,靶向胃饥饿素系统可能是阿片类使用障碍的可行治疗途径。
要点
- 羟考酮自我给药显著升高大鼠血浆胃饥饿素、去酰基胃饥饿素和生长激素,血浆LEAP2无变化。
- 选择性GHS-R1a拮抗剂JMV2959剂量依赖性减少Long-Evans大鼠羟考酮自我给药并降低渐进比率突破点。
- JMV2959的抑制作用由GHS-R1a选择性介导,在Wistar野生型大鼠有效而在GHS-R敲除大鼠无效。
核心结论
- 作者认为,羟考酮或羟考酮相关刺激升高胃饥饿素信号是羟考酮动机性摄药的原因性过程,靶向胃饥饿素系统可能是阿片类使用障碍的可行治疗途径。
研究设计与样本
- 研究在大鼠中探究内源性胃饥饿素系统与羟考酮自我给药行为的相互作用。
- 研究在小鼠中检验胃饥饿素系统对光遗传刺激中脑奖赏环路驱动的脑刺激奖赏的作用。
主要发现
- 羟考酮自我给药显著升高血浆胃饥饿素、去酰基胃饥饿素和生长激素,对血浆LEAP2无影响。
- 羟考酮自我给药显著降低血浆胃抑制多肽和胰岛素。
- 羟考酮自我给药获得显著上调腹侧被盖区(VTA)多巴胺神经元中GHS-R1a mRNA水平。
- JMV2959预处理剂量依赖性减少Long-Evans大鼠羟考酮自我给药,并降低渐进比率强化下羟考酮的突破点。
- JMV2959预处理显著抑制选择性刺激VTA多巴胺神经元驱动的脑刺激奖赏,但不抑制刺激投射至VTA的纹状体GABA神经元驱动的脑刺激奖赏。
关键数值与推荐
- JMV2959对羟考酮自我给药的抑制作用在Wistar野生型大鼠中表现相似,而在GHS-R敲除大鼠中不表现,表明该效应由GHS-R1a选择性介导。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ghrelin, an orexigenic hormone, has emerged as a critical biological substrate implicated in drug reward. However, the response of the ghrelin system to opioid-motivated behaviors and the role of ghrelin in oxycodone self-administration remain to be studied. Here, we investigated the reciprocal interactions between the endogenous ghrelin system and oxycodone self-administration behaviors in rats and the role of the ghrelin system in brain stimulation reward (BSR) driven by optogenetic stimulation of midbrain reward circuits in mice. Oxycodone self-administration significantly elevated plasma ghrelin, des-acyl ghrelin and growth hormone and showed no effect on plasma LEAP2, a newly identified endogenous ghrelin receptor (GHS-R1a) antagonist. Oxycodone self-administration produced significant decreases in plasma gastric inhibitory polypeptide and insulin. Acquisition of oxycodone self-administration significantly upregulated GHS-R1a mRNA levels in dopamine neurons in the ventral tegmental area (VTA), a brain region critical in drug reward. Pretreatment with JMV2959, a selective GHS-R1a antagonist, dose-dependently reduced oxycodone self-administration and decreased the breakpoint for oxycodone under a progressive ratio reinforcement in Long-Evans rats. The inhibitory effects of JMV2959 on oxycodone self-administration is selectively mediated by GHS-R1a as JMV2959 showed a similar effect in Wistar wildtype but not in GHS-R knockout rats. JMV2959 pretreatment significantly inhibited BSR driven by selective stimulation of VTA dopamine neurons, but not by stimulation of striatal GABA neurons projecting to the VTA in mice. These findings suggest that elevation of ghrelin signaling by oxycodone or oxycodone-associated stimuli is a causal process by which oxycodone motivates oxycodone drug-taking and targeting the ghrelin system may be a viable treatment approach for opioid use disorders.
引用
- You ZB, Gardner EL, Galaj E, et al. Involvement of the ghrelin system in the maintenance of oxycodone self-administration: converging evidence from endocrine, pharmacologic and transgenic approaches. Mol Psychiatry. 2022. PMID: 35064236. doi:10.1038/s41380-022-01438-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。